

# INVITATION

Breakfast  
symposium



Thursday,  
13th of February  
7:30

Congress Center Liège  
Auditoirium Rogier  
1st floor



**Dr. Tom Holvoet (PhD)**  
VITAZ / UZ Gent



**Prof. Dr. Claire Liefverinckx**  
Hôpital Erasme



**Dr. Filip Baert (PhD)**  
AZ Delta

Breakfast symposium  
13<sup>th</sup> February



## Innovations in IBD treatment: Local Insights on Subcutaneous Infliximab

### Agenda

- **7:30** : Welcome & Breakfast served
- **8:00** : Exploring impact of the transition from infliximab IV to SC administration (**AMARETTO preliminary data**).  
**Dr. Tom Holvoet (PhD)**  
VITAZ / UZ Gent
- **8:10** : Comparative study of infliximab IV and SC in IBD : Interim analysis of a prospective single center Cohort (**The SWITCH study**).  
**Prof. Dr. Claire Liefverinckx**  
Hôpital Erasme
- **8:20** : Real world experience of switching from infliximab IV to SC: Long term results including PK and biomarkers  
**Dr. Filip Baert (PhD)**  
AZ Delta

**IV** : Intravenous, **SC** : Subcutaneous,  
**IBD** : Inflammatory bowel disease,  
**PK** : Pharmacokinetics

HEALTHCARE  
**CELLTRION**

©Celltrion Healthcare BeLux B.V., 2024 | Culliganlaan 2F | 1830 Diegem | Belgium  
Tel + 32 (0)2 643 71 81 | BE-24-00021 December 2024